Clinical Trials Logo

Influenza clinical trials

View clinical trials related to Influenza.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06274359 Not yet recruiting - Influenza Clinical Trials

Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

While the COVID-19 pandemic has highlighted health disparities, Black children have unduly suffered and died from seasonal influenza for decades. Through sustained partnership with Black community stakeholders, novel community-engaged research methods, and an innovative intervention approach, this proposal will explore, develop, and test a Digital Storytelling intervention to reduce influenza vaccination disparities in Black children aged 6 months to 5 years. This project will advance our understanding of engagement methods and interventions that improve health equity and serve as a model for future work to address vaccination disparities, ensuring all individuals have the chance to fulfill their potential free of preventable diseases.

NCT ID: NCT06254313 Not yet recruiting - Influenza Clinical Trials

The Role of Cxcr4Hi neutrOPhils in InflueNza

CHOPIN
Start date: September 2024
Phase:
Study type: Observational

Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.

NCT ID: NCT06207058 Not yet recruiting - Influenza Clinical Trials

Evaluation of a Screen and Treat Protocol for Influenza

Start date: January 15, 2024
Phase:
Study type: Observational

This study seeks to demonstrate that the laboratory can mitigate respiratory virus transmission in underserved populations by using laboratory data to identify communities at risk for increase vial activity (hot spots) and intervening with a test-to-treat model provides increased access to influenza diagnostics and treatment in vulnerable and underserved communities.

NCT ID: NCT06075732 Not yet recruiting - COVID-19 Clinical Trials

ACTIVATE in Public Housing

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and increase influenza, meningitis, pneumonia, VZV, and COVID-19 vaccine rates among under-resourced African American and Latino public housing residents in South Los Angeles.

NCT ID: NCT06062264 Not yet recruiting - Influenza Clinical Trials

Patient Portal Flu Vaccine Reminders (RCT 6)

Start date: October 2, 2023
Phase: N/A
Study type: Interventional

This trial is taking place in Los Angeles, CA at 21 clinics within the UCLA Health System. The study design is a 3 arm randomized trial. Patients will be randomized into 1) receiving portal based reminder messages with a video from their PCP encouraging them to receive the influenza vaccine, 2) portal-based reminder messages with an infographic with the image of their PCP encouraging them to receive the influenza vaccine, or 3) the control group. Patients randomized to the intervention arms will receive reminders if they are due for influenza vaccine. Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above 6 months of age should receive an annual flu vaccine, vaccination rates remain low: at 6m-4.9 yrs. (70%), 5-17.9 yrs. (56%), 18-64.9 yrs. (38%), and >65 yrs. (63%). The investigators will assess the effectiveness of MyChart R/R video messages and infographic messages as compared to the standard of care control (Health system messages).

NCT ID: NCT05947071 Not yet recruiting - Influenza Clinical Trials

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

PSOT
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. One study compared HD-IIV vs. SD-IIV in adult SOT recipients and noted that HD-IIV was safe and more immunogenic; however, the median post-transplant period was 38 months. A phase I pediatric study comparing a single dose of HD-IIV vs. SD-IIV was safe with higher immunogenicity, but the study was limited by small sample size and median post-transplant vaccine administration was 26 months. In another phase II trial of adult SOT recipients, two doses of SD-IIV one month apart compared to one-dose of SD-IIV revealed modestly increased immunogenicity when given at a median of 18 months post-transplant. Therefore, these studies lack both evaluation in the early post-transplant period and substantive pediatric populations. Additionally, the administration of two-doses of HD-IIV in the same influenza season has not been evaluated in pediatric SOT recipients. Thus, the optimal immunization strategy for pediatric SOT recipients less than 24 months post-transplant is unknown. In addition, immunologic predictors and correlates of influenza vaccine immunogenicity in pediatric SOT recipients have not been well-defined. The central hypothesis of our proposal is that pediatric SOT recipients 1-23 months post-transplant who receive two doses of HD-quadrivalent inactivated influenza vaccine (QIV) will have similar safety but higher Hemagglutination Inhibition (HAI) geometric mean titers (GMTs) to influenza antigens compared to pediatric SOT recipients receiving two doses of SD-QIV.

NCT ID: NCT05832307 Not yet recruiting - Influenza Clinical Trials

The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program

Influential
Start date: November 17, 2023
Phase: N/A
Study type: Interventional

This study plans to learn more about whether a stakeholder-informed, standardized inpatient vaccination program will increase influenza vaccination rates of hospitalized children across US pediatric health systems. The first part of the study is to form a multidisciplinary team of stakeholders, including parents, providers, nurses, pharmacists, informaticists, data analysts and communication experts across three sites in synthesizing a best practice implementation guide for an inpatient influenza vaccination program, which will then be piloted at these three sites.

NCT ID: NCT05612893 Not yet recruiting - Influenza Clinical Trials

Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study

DISPLAY
Start date: November 16, 2022
Phase:
Study type: Observational

The goal of this observational study is to describe the immune signature of acute pulmonary infection.The main questions it aims to answer are: 1. Nasal mucosal immune response in patients with influenza infection 2. Difference of immune response between Viral sepsis and Bacterial sepsis 3. Immunological differences between Viral sepsis and Viral pneumonia

NCT ID: NCT05569239 Not yet recruiting - Influenza Clinical Trials

Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-55 years.

NCT ID: NCT05315024 Not yet recruiting - Influenza Clinical Trials

Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children

Start date: April 30, 2022
Phase: N/A
Study type: Interventional

Aims and hypotheses to be tested: Primary objective - To compare the IIV responses, in terms of seroconversion rates, using ID IIV with topical 5% imiquimod (IIV-Q-ID), ID influenza vaccine alone (IIV-ID), and the second dose of IM influenza vaccine (IIV-IM) among children who are IIV non-responders. Secondary objectives - To determine the IIV non-responder rate in healthy Hong Kong children. - To investigate the association between HLA molecules and IIV non-responsiveness. Hypotheses - The investigators hypothesize that among IIV non-responder children, the seroconversion rate after ID IIV with topical imiquimod will be significantly higher than a second IM IIV dose. - The investigators hypothesize that the IIV non-responder rate is approximately 5-10% in the paediatric population. - The investigators hypothesize that certain HLA alleles are associated with IIV non-responders.